Clinical trials: Healthy Male/Female Subjects
Healthy Young Volunteers, Healthy Elderly Volunteers
A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects
This is a single dose study in healthy male and female (of non-child bearing potential) volunteers, to assess the safety, effects on the body, and blood and urine drug levels of AZD3293.
- Trial name
- NCT01739647
- Testing
- AZD3293
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pharmacokinetic Analysis, Bioequivalence
Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects
Pivotal, single-dose, randomized, open-label, two-period, two-sequence, two-treatment, single-centre, crossover, bioequivalence study of Levetiracetam 1500 mg coated granules in sachet formulations and Keppra (Levetiracetam) 2 x…
- Conditions
- Pharmacokinetic Analysis, Bioequivalence, Health Adult Subjects
- Trial name
- NCT07393022
- Testing
- Levetiracetam 1500 mg, Keppra® 750 mg
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Desitin Arzneimittel GmbH
Hypertension
Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions
This is an open-label, single-centre, randomized, single dose, three-way crossover, six sequence study to evaluate the comparative bioavailability of two Fixed Dose Combination (FDC) tablet formulations of amlodipine and…
- Trial name
- NCT02075619
- Testing
- Amlodipine+Rosuvastatin, GSK3074477 FDC - 1, GSK3074477 FDC - 2
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Impairment
Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.
To characterize the pharmacokinetics and safety of buparlisib following a single 50 mg oral dose in subjects with moderate and severe renal impairment.
- Trial name
- NCT02048787
- Testing
- Buparlisib
- Where
- 4 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Solid Tumours
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in subjects with renal impairment and healthy subjects
- Trial name
- NCT02063204
- Testing
- selumetinib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Insufficiency
A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment.
- Trial name
- NCT03545087
- Testing
- Lanabecestat, Iohexol
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
The primary purpose of this study is to compare the PK parameters of a single dose of a test tablet formulation of AKB-6548 relative to a single dose of the reference AKB-6548 tablet formulation, both treatments administered…
- Trial name
- NCT02412449
- Testing
- AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Healthy
Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (600 mg loading dose followed by 4 days 150 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with omeprazole 80 mg/day compared to…
- Trial name
- NCT01129414
- Testing
- Clopidogrel, Omeprazole
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Metabolism and Nutrition Disorder, Obesity
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC…
- Trial name
- NCT01044108
- Testing
- NNC 0070-0002-0453, '2-0453
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Subjects, Cardiac Repolarization
A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects
The objective of this study is to evaluate the effect of repeat oral dosing of ASP1941 on electrocardiogram (ECG) measurements.
- Trial name
- NCT01232413
- Testing
- ASP1941, Moxifloxacin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Healthy
AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects
This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects
- Trial name
- JSAD/JMAD (NCT00785915)
- Testing
- AZD6765
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
GW823296 Repeat Dose Study In Healthy Male And Female Subjects
This is a study to evaluate the safety, tolerability and pharmacokinetics of GW823296 following 28 days, once-daily repeat oral doses.
- Trial name
- NCT00675116
- Testing
- GW823296
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine
Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.
- Trial name
- NCT01209741
- Testing
- telcagepant potassium, MK-0974 5Mo5C, MK-0974 12Mo5C
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®)
- Trial name
- NCT02262572
- Testing
- Telmisartan /HCTZ - compression tablet (DC), Telmisartan /HCTZ - dry granulation tablet (DG), Telmisartan /HCTZ - present commercial formulation
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Biological Availability
Bioavailability of Omega-3 Food Supplement in Healthy Subjects
The study will evaluate the relative bioavailability of Pronovum PRF-037 and Pronovum PRF-041 with PronovaPure 150:150 EE EU and Eskimo-3 (500 mg omega-3 acid triglyceride containing 80 mg EPA and 50 mg DHA per gram oil) in…
- Trial name
- NCT02376608
- Testing
- Pronova Pure 150:500 EE EU, Pronovum PRF-037, Pronovum PRF-041
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pronova BioPharma
Healthy Volunteers, Pharmacokinetics of ASP1941
Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults
This is a study of the pharmacokinetic profile and safety and tolerability of ASP1941after repeat dosing and the effect of ASP1941 on glucose levels in non elderly and elderly healthy adult male and female subjects.
- Trial name
- NCT01678287
- Testing
- ASP1941
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Drug Interactions
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
The purpose of this study is to evaluate the effects of steady-state telotristat ethyl on the pharmacokinetics (PK) of single-dose fexofenadine in healthy subjects.
- Trial name
- NCT02157558
- Testing
- Fexofenadine, Telotristat etiprate
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Overweight and Obesity
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects
- Trial name
- NCT06714825
- Testing
- HS235
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- 35Pharma Inc., a GSK company
Anxiety Disorders
Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
This study will be conducted to evaluate and compare the single oral dose bioavailability of Paroxetine manufactured by GlaxoSmithKline (GSK) Pharmaceuticals S.A. for GlaxoSmithKline México, S.A. de C.V.
- Trial name
- NCT04311463
- Testing
- Paroxetine hydrochloride, PAXIL (Paroxetine hydrochloride )
- Where
- Mexico
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
Comparison of pharmacokinetics of dipyridamole administered as Aggrenox versus dipyridamole administered as the immediate release formulation plus aspirin, under conditions of reduced stomach acidity.
- Trial name
- NCT02251184
- Testing
- Aggrenox, Dipyridamole, Aspirin
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim